Abnormality in glutamine–glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study
Open Access
- 1 March 2016
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 6 (3) , e744
Abstract
Major depressive disorder (MDD), common in the elderly, is a risk factor for dementia. Abnormalities in glutamatergic neurotransmission via the N-methyl-d-aspartate receptor (NMDA-R) have a key role in the pathophysiology of depression. This study examined whether depression was associated with cerebrospinal fluid (CSF) levels of NMDA-R neurotransmission-associated amino acids in cognitively intact elderly individuals with MDD and age- and gender-matched healthy controls. CSF was obtained from 47 volunteers (MDD group, N=28; age- and gender-matched comparison group, N=19) at baseline and 3-year follow-up (MDD group, N=19; comparison group, N=17). CSF levels of glutamine, glutamate, glycine, l-serine and d-serine were measured by high-performance liquid chromatography. CSF levels of amino acids did not differ across MDD and comparison groups. However, the ratio of glutamine to glutamate was significantly higher at baseline in subjects with MDD than in controls. The ratio decreased in individuals with MDD over the 3-year follow-up, and this decrease correlated with a decrease in the severity of depression. No correlations between absolute amino-acid levels and clinical variables were observed, nor were correlations between amino acids and other biomarkers (for example, amyloid-β42, amyloid-β40, and total and phosphorylated tau protein) detected. These results suggest that abnormalities in the glutamine–glutamate cycle in the communication between glia and neurons may have a role in the pathophysiology of depression in the elderly. Furthermore, the glutamine/glutamate ratio in CSF may be a state biomarker for depression.Keywords
This publication has 45 references indexed in Scilit:
- Targeting of NMDA receptors in new treatments for schizophreniaExpert Opinion on Therapeutic Targets, 2014
- Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studiesThe British Journal of Psychiatry, 2013
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disordersEuropean Archives of Psychiatry and Clinical Neuroscience, 2013
- The Glutamate–Glutamine (GABA) Cycle: Importance of Late Postnatal Development and Potential Reciprocal Interactions between Biosynthesis and DegradationFrontiers in Endocrinology, 2013
- Midlife vs Late-Life Depressive Symptoms and Risk of DementiaArchives of General Psychiatry, 2012
- Glutamatergic Modulators: The Future of Treating Mood Disorders?Harvard Review of Psychiatry, 2010
- High Occurrence of Mood and Anxiety Disorders Among Older AdultsArchives of General Psychiatry, 2010
- Emerging role of glutamate in the pathophysiology of major depressive disorderBrain Research Reviews, 2009
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersNature Reviews Drug Discovery, 2008
- Depression and Risk for Alzheimer DiseaseArchives of General Psychiatry, 2006